Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation. Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients to receive, in combi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Soc Nephrol
Autors principals: Pascual, Julio, Berger, Stefan P., Witzke, Oliver, Tedesco, Helio, Mulgaonkar, Shamkant, Qazi, Yasir, Chadban, Steven, Oppenheimer, Federico, Sommerer, Claudia, Oberbauer, Rainer, Watarai, Yoshihiko, Legendre, Christophe, Citterio, Franco, Henry, Mitchell, Srinivas, Titte R., Luo, Wen-Lin, Marti, AnaMaria, Bernhardt, Peter, Vincenti, Flavio
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2018
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050928/
https://ncbi.nlm.nih.gov/pubmed/29752413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018010009
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars